Abstract: The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues.

Abstract: The present invention relates to a method for the in vitro determination of the presence of or a predisposition of a patient to the development of cancer. In the method according to the invention, the presence of a marker is determined in a biological sample of the patient, said marker being selected from a) the amino acid sequence SEQ ID Nr. 2 from the sequence protocol that is provided, or b) a nucleic acid that encodes the amino acid sequence with the SEQ ID Nr. 2. The invention further relates to the amino acid and the encoding nucleic acid and to the use thereof in diagnostics and for molecular therapeutic approaches.

Abstract: The present invention relates to a method for the implantation of biological material into an organism.

Abstract: The present invention relates to a fusion protein comprising a) a first polypeptide selected from among SDF-1 (stromal cell derived factor-1) or peptidase/protease-resistant variants or fragments thereof which have the CXCR4-/CXCR7- binding function of SDF-1; and b) a second polypeptide which is selected from among GPVI (glycoprotein VI), or the extracellular domain of GPVI, or fragments or variants of the extracellular domain of GPVI which contain the collagen binding function of GPVI, wherein the first polypeptide and the second peptide are linked to one another directly or via a linker molecule. The invention furthermore relates to the use of the fusion protein for treating diseases.

Abstract: The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.

Abstract: The present invention relates to a method for the visual examination of biological material ex vivo and an apparatus for the sterical orientation of biological material which can be used in said method.

Abstract: The invention relates to a free-wheel, in particular a pinch roller free-wheel or a pinch body free-wheel, comprising relatively-rotating elements arranged one within the other on a common axis, which form a gap, in which pinch elements, in particular pinch rollers or pinch bodies, are arranged such that a friction connection can be produced with the facing outer surfaces of the elements, by means of the pinch surfaces, whereby the free-wheel outer rim is covered by a ring of fibre-reinforced plastic and the external diameter of the ring of fibre-reinforced plastic is about 1.3 to 1.8 times the diameter of the external clamping surface.

Abstract: The invention relates to a free-wheel, in particular a pinch roller free-wheel or a pinch body free-wheel, comprising relatively-rotating elements arranged one within the other on a common axis, which form a gap, in which pinch elements, in particular pinch rollers or pinch bodies, are arranged such that a friction connection can be produced with the facing outer surfaces of the elements, by means of the pinch surfaces, whereby the free-wheel outer rim is covered by a ring of fibre-reinforced plastic and the external diameter of the ring of fibre-reinforced plastic is about 1.3 to 1.8 times the diameter of the external clamping surface.

Abstract: Abstract of the Disclosure: Catalyst systems for the polymerization of C.sub.2 -C.sub.10 -alk-1-enes contain, as active components,a) a metallocene complex of the general formula I ##STR1## where M is titanium, zirconium, hafnium, vanadium, niobium or tantalum, X is halogen or C.sub.1 -C.sub.8 -alkyl, Y is carbon, phosphorus, sulfur, silicon or germanium, Z is C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl or C.sub.6 -C.sub.10 -aryl, R.sup.1 and R.sup.2 are identical or different and are each C.sub.1 -C.sub.4 -alkyl, R.sup.3 to R.sup.6 are identical or different and are each hydrogen or C.sub.1 -C.sub.8 -alkyl, or two adjacent radicals R.sup.3 and R.sup.4 and R.sup.5 and R.sup.6 in each case together form a hydrocarbon ring system of 4 to 15 carbon atoms and n is 0, 1 or 2, andb) an open-chain or cyclic alumoxane compound of the general formula II or III ##STR2## where R.sup.7 is C.sub.1 -C.sub.4 -alkyl and n is from 5 to 30.

Abstract: Catalyst systems for the polymerization of C.sub.2 -C.sub.10 -alk-1-enes contain, as active components,a) a metallocene complex of the general formula I ##STR1## where M is titanium, zirconium, hafnium, vanadium, niobium or tantalum, X is halogen or C.sub.1 -C.sub.8 -alkyl, Y is carbon, phosphorus, sulfur, silicon or germanium, Z is C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl or C.sub.6 -C.sub.10 -aryl, R.sup.1 and R.sup.2 are identical or different and are each C.sub.1 -C.sub.4 -alkyl, R.sup.3 to R.sup.6 are identical or different and are each hydrogen or C.sub.1 -C.sub.8 -alkyl, or two adjacent radicals R.sup.3 and R.sup.4 and R.sup.5 and R.sup.6 in each case together form a hydrocarbon ring system of 4 to 15 carbon atoms and n is 0, 1 or 2, andb) an open-chain or cyclic alumoxane compound of the general formula II or III ##STR2## where R.sup.7 is C.sub.1 -C.sub.4 -alkyl and n is from 5 to 30.

Abstract: Catalyst systems for the polymerization of C.sub.2 -C.sub.10 -alk-1-enes contain, as active components,a) a metallocene complex of the general formula I ##STR1## where M is titanium, zirconium, hafnium, vanadium, niobium or tantalum, X is halogen or C.sub.1 --C.sub.8 -alkyl, Y is carbon, phosphorus, sulfur, silicon or germanium, Z is C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.10 -cycloalkyl or C.sub.6 -C.sub.10 -aryl, R.sup.1 and R.sup.2 are identical or different and are each C.sub.1 -C.sub.4 -alkyl, R.sup.3 to R.sup.6 are identical or different and are each hydrogen or C.sub.1 -C.sub.8 -alkyl, or two adjacent radicals R.sup.3 and R.sup.4 and R.sup.5 and R.sup.6 in each case together form a hydrocarbon ring system of 4 to 15 carbon atoms and n is 0, 1 or 2, andb) an open-chain or cyclic alumoxane compound of the general formula II or III ##STR2## where R.sup.7 is C.sub.1 -C.sub.4 -alkyl and n is from 5 to 30.